

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent

Ghanima



| Section 1. Identifying Inform   | nation                            |                            |                                      |
|---|-----------------------------------|----------------------------|--------------------------------------|
| 1. Given Name (First Name)<br>Waleed  | 2. Surname (Last Name)<br>Ghanima |                            | 3. Date<br>04-December-2013          |
| 4. Are you the corresponding author?  | ✔ Yes No                          |                            |                                      |
| 5. Manuscript Title<br>Bone marrow fibrosis in 66 Immune Th<br>receptor agonists: a single center long-<br>6. Manuscript Identifying Number (if you k<br>HAEMATOL/2013/098921   | term follow-up                    | treated with thrombopc     | bietin                               |
| Section 2. The Work Under C   | onsideration for Public           | cation                     |                                      |
| Did you or your institution <b>at any time</b> rece<br>any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of inter | g but not limited to grants, da   |                            |                                      |
| Section 3. Relevant financial   | activities outside the s          | ubmitted work.             |                                      |
| Place a check in the appropriate boxes<br>of compensation) with entities as descr<br>clicking the "Add +" box. You should re  | ibed in the instructions. Us      | se one line for each entit | ty; add as many lines as you need by |
| Are there any relevant conflicts of inter   | est? 🖌 Yes 🗌 No                   |                            |                                      |
| If yes, please fill out the appropriate inf   | ormation below.                   |                            |                                      |
| Name of Entity  | Grant                             | n-Financial Other?         | Comments                             |
| AMGEN   | <b>~</b>                          |                            | onsultancy                           |
| GlaxoSmithKline   |                                   |                            |                                      |
|   |                                   |                            |                                      |
| Continue  |                                   |                            |                                      |
| Section 4. Intellectual Prope   | rty Patents & Copyrig             | yhts                       |                                      |
| Do you have any patents, whether plar   | ned, pending or issued, br        | oadly relevant to the wo   | ork? Yes 🖌 No                        |



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ghanima reports grants, personal fees and other from AMGEN, personal fees from GlaxoSmithKline, outside the submitted work; .

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Info  | rmation  |  |
|--|--|--|
| 1. Given Name (First Name)<br>Julia  | 2. Surname (Last Name)<br>Geyer  | 3. Date<br>04-December-2013  |
| 4. Are you the corresponding author?   | Yes 🖌 No   | Corresponding Author's Name<br>Waleed Ghanima  |
| <ol> <li>Manuscript Title</li> <li>Bone marrow fibrosis in 66 Immune</li> <li>receptor agonists: a single center lon</li> <li>Manuscript Identifying Number (if you</li> <li>HAEMATOL/2013/098921</li> </ol> | g-term follow-up   | reated with thrombopoietin   |
| Section 2. The Work Under  | Consideration for Public   | ation  |
| · · ·  | ing but not limited to grants, da  | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3. Relevant financi  | al activities outside the s  | ubmitted work.   |
| Place a check in the appropriate boxe<br>of compensation) with entities as des   | es in the table to indicate who<br>cribed in the instructions. Us<br>report relationships that wer | ether you have financial relationships (regardless of amount<br>e one line for each entity; add as many lines as you need by<br>e <b>present during the 36 months prior to publication</b> . |
| Section 4. Intellectual Prop   | erty Patents & Copyrig   | hts  |
| Do you have any patents, whether pl  | anned, pending or issued, br   | oadly relevant to the work? Yes 🖌 No   |



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Geyer has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent



| Section 1.   | Identifying Inform  | ation   |  |   |
|--|---|---|--|---|
| _  |   |   |  |   |
| 1. Given Name (Fi<br>Christina S.                      | rst Name)   | 2. Surname (Last Name)<br>Lee   |  | 3. Date<br>04-December-2013   |
| 4. Are you the cor                                     | responding author?  | Yes 🖌 No  | Corresponding Author's Nam<br>Waleed Ghanima                     | ne  |
| receptor agonist<br>6. Manuscript Ider<br>HAEMATOL/201 | prosis in 66 Immune Thr<br>ts: a single center long-t<br>ntifying Number (if you kn | term follow-up  | reated with thrombopoietin                                       | 1   |
| Section 2.   | The Work Under Co   | onsideration for Public   | ation  |   |
| any aspect of the s<br>statistical analysis,           | ubmitted work (including  | but not limited to grants, da   | a third party (government, com<br>ta monitoring board, study des | nmercial, private foundation, etc.) for<br>ign, manuscript preparation,                           |
| Section 3.   | Relevant financial  | activities outside the s  | ubmitted work.   |   |
| of compensatior clicking the "Adc                      | the appropriate boxes i<br>ı) with entities as descri                               | n the table to indicate whe<br>bed in the instructions. Us<br>port relationships that wer | ether you have financial rela<br>e one line for each entity; ac  | tionships (regardless of amount<br>dd as many lines as you need by<br>onths prior to publication. |
| Section 4.   | Intellectual Proper   | ty Patents & Copyrig  | hts  |   |
| Do you have any  | patents, whether plan   | ned, pending or issued, br  | oadly relevant to the work?                                      | Yes 🖌 No  |



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Lee has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### **Relationships not covered above.**

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent

Boiocchi



| Section 1. Identify   | ring Information  |   |
|---|---|---|
| 1. Given Name (First Name)<br>Leonardo  | 2. Surname (Last Name)<br>Boiocchi  | 3. Date<br>04-December-2013   |
| 4. Are you the corresponding  | author? Yes 🖌 No  | Corresponding Author's Name<br>Waleed Ghanima   |
| <ol> <li>Manuscript Title</li> <li>Bone marrow fibrosis in 66</li> <li>receptor agonists: a single</li> <li>Manuscript Identifying Nur</li> <li>HAEMATOL/2013/098921</li> </ol> |   | treated with thrombopoietin   |
| Section 2. The Wor  | k Under Consideration for Publi   | ication   |
|   | ork (including but not limited to grants, d   | n a third party (government, commercial, private foundation, etc.) for<br>ata monitoring board, study design, manuscript preparation,   |
| Section 3. Relevan  | t financial activities outside the  | submitted work.   |
| Place a check in the approp<br>of compensation) with enti   | riate boxes in the table to indicate wh<br>ties as described in the instructions. U<br>ou should report relationships that we | nether you have financial relationships (regardless of amount<br>Jse one line for each entity; add as many lines as you need by<br>ere <b>present during the 36 months prior to publication</b> . |
| Section 4. Intellect  | ual Property Patents & Copyri   | ahts  |
|   | /hether planned, pending or issued, b   |   |



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Boiocchi has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent

Imahiyerobo



| Section 1. Ident                                    | tifying Information  |  |  |                           |  |  |  |
|---|--|--|--|---------------------------|--|--|--|
| 1. Given Name (First Name<br>Allison                | e) 2. Surnam<br>Imahiyer   | ne (Last Name)<br>obo                                | 3. Date<br>04-Dec  | e<br>cember-2013          |  |  |  |
| 4. Are you the correspond                           | ing author?  | Yes Vo Corresponding Author's Name<br>Waleed Ghanima |  |                           |  |  |  |
|   | le center long-term follow<br>Number (if you know it)                                      |  | eated with thrombopoietin  |                           |  |  |  |
| Section 2. The W                                    | Vork Under Considerat  | ion for Public                                       | ation  |                           |  |  |  |
| Did you or your institution                         | <b>at any time</b> receive payment<br>d work (including but not limi<br>                   | or services from a                                   | third party (government, commercia<br>a monitoring board, study design, ma   |                           |  |  |  |
| Section 3. Relev                                    | ant financial activities   | outside the su                                       | bmitted work.  |                           |  |  |  |
| Place a check in the app<br>of compensation) with e | ropriate boxes in the table<br>ntities as described in the<br>. You should report relation | to indicate whe<br>instructions. Use                 | ther you have financial relationshi<br>one line for each entity; add as m<br><b>present during the 36 months</b> ( | hany lines as you need by |  |  |  |
| Section 4. Intell                                   | ectual Property Pate   | nts & Convria  | nts  |                           |  |  |  |
|   | s, whether planned, pendi  |  |  | es 🖌 No                   |  |  |  |



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Allison Imahiyerobo, NP has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

2.

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### **Relationships not covered above.**

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent



| Section 1.  | entifying Informati                               | ion   |   |  |
|---|---|---|---|--|
| 1. Given Name (First Na<br>Attilio                      |   | . Surname (Last Name)<br>Drazi                      |   | 3. Date<br>04-December-2013  |
| 4. Are you the correspo                                 | onding author?                                    | Yes 🖌 No  | Corresponding Author's Na<br>Waleed Ghanima                       | me   |
| receptor agonists: a s                                  | single center long-terr<br>ng Number (if you know | n follow-up   | treated with thrombopoieti  | in   |
| Section 2. The  | e Work Under Cons                                 | sideration for Publ                                 | ication   |  |
| any aspect of the submi<br>statistical analysis, etc.)? | itted work (including bu                          | t not limited to grants, d                          | n a third party (government, co<br>ata monitoring board, study de | mmercial, private foundation, etc.) for<br>esign, manuscript preparation,                                    |
| Section 3. Rel  | levant financial act                              | tivities outside the                                | submitted work.   |  |
| of compensation) wit<br>clicking the "Add +" b          | th entities as described                          | d in the instructions. L<br>t relationships that we | Ise one line for each entity; a                                   | ationships (regardless of amount<br>add as many lines as you need by<br><b>nonths prior to publication</b> . |
| Section 4. Int  | ellectual Property                                | Patents <u>&amp; Copyri</u>                         | ights   |  |
|   |   |   | oroadly relevant to the work?                                     | ? Yes 🖌 No   |



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Orazi has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

## 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1.                | Identifying Infor   | mation              |                |   |  |
|---------------------------|---------------------|---------------------|----------------|---|--|
| 1. Given Name (F<br>James | irst Name)          | 2. Surnar<br>Bussel | ne (Last Name) |   | 3. Effective Date (07-August-2008)<br>04-December-2013 |
| 4. Are you the co         | rresponding author? | Yes                 | V No           | Corresponding Author's Na<br>Waleed Ghanima | nme  |
| 5 Manuscript Titl         | ۵                   |                     |                |   |  |

Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up

6. Manuscript Identifying Number (if you know it)

HAEMATOL/2013/098921

# Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

| The Work Under Consideration for Publication   |    |                         |                                  |                |            |     |
|--|----|-------------------------|----------------------------------|----------------|------------|-----|
| Туре   | No | Money<br>Paid<br>to You | Money to<br>Your<br>Institution* | Name of Entity | Comments** |     |
| 1. Grant   | ✓  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            | ADD |
| 2. Consulting fee or honorarium  | ✓  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            | ADD |
| 3. Support for travel to meetings for the study or other purposes  | ~  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            | ADD |
| <ol> <li>Fees for participation in review<br/>activities such as data monitoring<br/>boards, statistical analysis, end<br/>point committees, and the like</li> </ol> | ✓  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            | ADD |
| 5. Payment for writing or reviewing the manuscript   | ~  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            | ADD |
| <ol> <li>Provision of writing assistance,<br/>medicines, equipment, or<br/>administrative support</li> </ol>   | ~  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            |     |

Bussel



| The Work Under Consideration for Publication |    |                         |                                  |                |            |     |
|--|----|-------------------------|----------------------------------|----------------|------------|-----|
| Туре   | No | Money<br>Paid<br>to You | Money to<br>Your<br>Institution* | Name of Entity | Comments** |     |
|  |    |                         |                                  |                |            | ADD |
| 7. Other                                     | ~  |                         |                                  |                |            | ×   |
|  |    |                         |                                  |                |            | ADD |

\* This means money that your institution received for your efforts on this study.

\*\* Use this section to provide any needed explanation.

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

| Relevant financial activities outside the submitted work |    |                         |                                  |                 |          |     |
|--|----|-------------------------|----------------------------------|-----------------|----------|-----|
| Type of Relationship (in<br>alphabetical order)          | No | Money<br>Paid to<br>You | Money to<br>Your<br>Institution* | Entity          | Comments |     |
| 1. Board membership                                      | ~  |                         |                                  |                 |          | ×   |
|  |    |                         |                                  |                 |          | ADD |
| 2. Consultancy   |    | ✓                       |                                  | Portola         |          | ×   |
| 2. Consultancy   |    | ✓                       |                                  | Amgen           | Ad Board | ×   |
| 2. Consultancy   |    | •                       |                                  | Eisai           | Ad Board | ×   |
| 2. Consultancy   |    | •                       |                                  | GlaxoSmithKline | Ad Board | ×   |
| 2. Consultancy   |    | ✓                       |                                  | Ligand          | Ad Board | ×   |
| 2. Consultancy   |    | ✓                       |                                  | Shionogi        | Ad Board | ×   |
| 2. Consultancy   |    | •                       |                                  | Symphogen       | Ad Board | ×   |
|  |    |                         |                                  |                 |          | ADD |
| 3. Employment  | ~  |                         |                                  |                 |          | ×   |
|  |    |                         |                                  |                 |          | ADD |
| 4. Expert testimony                                      | ~  |                         |                                  |                 |          | ×   |



| Relevant financial activities outside the submitted work   |          |                         |                                  |                 |  |     |
|--|----------|-------------------------|----------------------------------|-----------------|--|-----|
| Type of Relationship (in<br>alphabetical order)  | No       | Money<br>Paid to<br>You | Money to<br>Your<br>Institution* | Entity          | Comments   |     |
|  |          |                         |                                  |                 |  | ADD |
| 5. Grants/grants pending   | ~        |                         |                                  |                 |  | ×   |
|  |          |                         |                                  |                 |  | ADD |
| 6. Payment for lectures including<br>service on speakers bureaus                                     | ~        |                         |                                  |                 |  | ×   |
|  |          |                         |                                  |                 |  | ADD |
| 7. Payment for manuscript preparation  | <b>~</b> |                         |                                  |                 |  | ×   |
|  |          |                         |                                  |                 |  | ADD |
| 8. Patents (planned, pending or issued)  | •        |                         |                                  |                 |  | ×   |
|  | _        | _                       | _                                |                 |  | ADD |
| 9. Royalties   | ~        |                         |                                  |                 |  | ×   |
|  |          |                         |                                  |                 |  | ADD |
| 10. Payment for development of educational presentations   | •        |                         |                                  |                 |  | ×   |
|  |          |                         |                                  |                 | ····· form: it. · ····· of a play in                               | ADD |
| 11. Stock/stock options  |          | •                       |                                  | Amgen           | my family own stocks in<br>portfolio, i have no<br>control over it | ×   |
| 11. Stock/stock options  |          | ~                       |                                  | GlaxoSmithKline | my family own stocks in<br>portfolio, i have no<br>control over it | ×   |
|  |          |                         |                                  |                 |  | ADD |
| <ol> <li>Travel/accommodations/<br/>meeting expenses unrelated to<br/>activities listed**</li> </ol> | •        |                         |                                  |                 |  | ×   |
|  |          |                         |                                  |                 |  | ADD |
| 13. Other (err on the side of full disclosure)   |          | ~                       |                                  | Amgen           | Clinical Research Support  | ×   |
| 13. Other (err on the side of full disclosure)   |          | •                       |                                  | Cangene         | Clinical Research Support  | ×   |
| 13. Other (err on the side of full disclosure)   |          | •                       |                                  | GlaxoSmithKline | Clinical Research Support  | ×   |
| 13. Other (err on the side of full disclosure)   |          | ~                       |                                  | Genzyme         | Clinical Research Support  | ×   |



| 13. Other (err on the side of full disclosure) | ~ | IgG of America | Clinical Research Support | × |
|--|---|----------------|---------------------------|---|
| 13. Other (err on the side of full disclosure) | ~ | Immunomedics   | Clinical Research Support | × |
| 13. Other (err on the side of full disclosure) | ~ | Ligand         | Clinical Research Support | × |
| 13. Other (err on the side of full disclosure) | ~ | Eisai          | Clinical Research Support | × |
| 13. Other (err on the side of full disclosure) | ~ | Shionogi       | Clinical Research Support | × |
| 13. Other (err on the side of full disclosure) | ~ | Sysmex         | Clinical Research Support | × |
|  |   |                |                           |   |

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

## Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

▶ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE

## **Evaluation and Feedback**